Generic drug lobby taps former BIO exec as new CEO

Taking stock of the drug industry, from the lab to the medicine chest

October 2, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy Patrick O'Connor STAT+ | $400 million for an obesity drug startup? A new venture is a sign of the times Atlas Venture, Bain Capital Life Sciences, and RTW Investments co-led a Series A financing for the company, to be led by industry veteran Ron Renaud. By Allison DeAngelis STAT+ | Opinion: Five things FDA ad comm members want After interviewing 30 current and former ad comm members, the Federation of American Scientists has five proposals. By Cheri Banks STAT+ | An obesity startup wastes no time: With drugs in early testing, Metsera lines up manufacturing A new deal with Amneal Pharmaceuticals is a reflection of how far ahead companies in the field have to plan manufacturing in order to be able to compete. By Elaine Chen Kevin Dietsch/Getty Images STAT+ | U.S. lawmaker urges FDA to clarify drug patent listings in a key government registry Bill Cassidy referred a registry that holds a key, behind-the-scenes role in shaping the competitive landscape of the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser